Bladder Cancer

Health Care Utilization and Costs Associated With Blue-Light vs White-Light Cystoscopy: A Real-World Bladder Cancer Population. August 10, 2026

Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice. August 7, 2026

En-bloc Resection of Bladder Tumor Versus Conventional Transurethral Resection of Bladder Tumor: Long-term Oncological Outcomes from a Single-center Prospective Trial. August 6, 2026

Comparison of Sex-Specific Treatment Outcomes in Clinical Trials and Subsequent Real-World Data on Systemic Therapies for Urothelial Carcinoma: A Systematic Review. August 6, 2026

ERBB2 Copy Number Alterations and Protein Expression in Bladder Cancer Treated by Cystectomy. August 5, 2026

Suicide risk among urinary bladder cancer patients compared with the standard population: a nationwide study in Sweden. August 4, 2026

Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. August 4, 2026

Performance of Urine Tumor DNA Detection in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Repeat Transurethral Resection. August 3, 2026

Antibody Drug Conjugates in Urothelial Carcinoma: Current Evidence and Practice Considerations. July 31, 2026

Squamous Cell Carcinoma of the Bladder: Current Evidence, Therapeutic Challenges, and Research Perspectives from the French AVENTUR Group. July 31, 2026

Prognostic significance of non-muscle-invasive late recurrence after intravesical bacillus Calmette-Guérin therapy in bladder cancer: a multicenter, retrospective real-world study (the Japan Urological Oncology Group). August 10, 2026

Integrating clinically actionable biomarkers into bladder cancer care - recommendations from the International Bladder Cancer Group. August 7, 2026

Oncological outcomes of extended versus standard pelvic lymph node dissection in radical cystectomy: An updated systematic review and meta-analysis. August 6, 2026

Association between time from diagnosis to radical cystectomy and oncologic outcomes in muscle-invasive urothelial carcinoma of the bladder. August 5, 2026

Paclitaxel and carboplatin after disease progression on immune checkpoint inhibitor for patients with metastatic urothelial carcinoma. August 4, 2026

Symptom-guided reduction of BCG dwell time: findings from the north-REG randomized trial. August 4, 2026

Oncological Outcomes and Prognostic Factors of Platinum-Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum-Based Chemotherapy Alone: A Propensity Score-Matched Analysis in a Real-World Population. August 4, 2026

Real-world Impact of Integrating Comprehensive Geriatric Assessment into Clinical Treatment Decision-making for Older Patients with Bladder Cancer. August 3, 2026

Perioperative therapy in muscle-invasive bladder cancer: real-world evidence from the MINOTAURO study. July 31, 2026

A Machine-Learning Approach to Predict Additional Treatment after Bacillus Calmette-Guérin Induction in Non-Muscle-Invasive Bladder Cancer - Beyond the Abstract July 30, 2026

Page 1 of 609